drugset / Trial / NCT06877650
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.
Timeline
- Start
- 2025-04-11
- Primary completion
- 2028-03-30
- Completion
- 2029-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JMT108 | Unknown | — | Intravenous |
| Background | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |